Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

被引：0
|
作者：
Hanfang Jiang
Huiping Li
Guohong Song
Lijun Di
Bin Shao
Ying Yan
Xiaoran Liu
Yifei Chen
Ruyan Zhang
Ran Ran
Yaxin Liu
Xinyu Gui
Nan Wang
Huan Wang
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology
来源：
Breast Cancer Research and Treatment | 2023年 / 199卷
关键词：
Pegylated liposomal doxorubicin; Metastatic breast cancer; HER2-negative; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：67 / 79
页数：12
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
    Chia, Stephen
    Clemons, Mark
    Martin, Lee-Ann
    Rodgers, Angela
    Gelmon, Karen
    Pond, Gregory R.
    Panasci, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
  • [32] A phase II, multicenter, single-arm study of eribulin mesilate as first-line therapy for HER2-negative locally advanced or metastatic breast cancer.
    Tei, Seika
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Kawajiri, Hidemi
    Tokunaga, Shinya
    Nishimura, Shigehiko
    Yamagata, Shigehito
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Tsuyoshi
    Tezuka, Kenji
    Noda, Satoru
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    Blum, Joanne L.
    Savin, Michael A.
    Edelman, Gerald
    Pippen, John E.
    Robert, Nicholas J.
    Geister, Brian V.
    Kirby, Robert L.
    Clawson, Alicia
    O'Shaughnessy, Joyce A.
    CLINICAL BREAST CANCER, 2007, 7 (11) : 850 - 856
  • [34] Phase II Trial of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Metastatic Breast Cancer Patients
    Jacquin, Jean-Philippe
    Chargari, Cyrus
    Thorin, Julie
    Mille, Dominique
    Melis, Adrien
    Orfeuvre, Hubert
    Clavreul, Guillaume
    Chaigneau, Loic
    Nourissat, Alice
    Dumanoir, Chantal
    Savary, Jacqueline
    Merrouche, Yacine
    Magne, Nicolas
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01): : 18 - 21
  • [35] A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    Schuler, Martin
    Awada, Ahmad
    Harter, Philipp
    Canon, Jean Luc
    Possinger, Kurt
    Schmidt, Marcus
    De Greve, Jacques
    Neven, Patrick
    Dirix, Luc
    Jonat, Walter
    Beckmann, Matthias W.
    Schuette, Jochen
    Fasching, Peter A.
    Gottschalk, Nina
    Besse-Hammer, Tatiana
    Fleischer, Frank
    Wind, Sven
    Uttenreuther-Fischer, Martina
    Piccart, Martine
    Harbeck, Nadia
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 1149 - 1159
  • [36] Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
    Pernas, Sonia
    Martin, Miguel
    Kaufman, Peter A.
    Gil-Martin, Marta
    Gomez Pardo, Patricia
    Lopez-Tarruella, Sara
    Manso, Luis
    Ciruelos, Eva
    Alejandro Perez-Fidalgo, Jose
    Hernando, Cristina
    Ademuyiwa, Foluso O.
    Weilbaecher, Katherine
    Mayer, Ingrid
    Pluard, Timothy J.
    Martinez Garcia, Maria
    Vahdat, Linda
    Perez-Garcia, Jose
    Wach, Achim
    Barker, Debra
    Fung, Samson
    Romagnoli, Barbara
    Cortes, Javier
    LANCET ONCOLOGY, 2018, 19 (06): : 812 - 824
  • [37] A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    Martin Schuler
    Ahmad Awada
    Philipp Harter
    Jean Luc Canon
    Kurt Possinger
    Marcus Schmidt
    Jacques De Grève
    Patrick Neven
    Luc Dirix
    Walter Jonat
    Matthias W. Beckmann
    Jochen Schütte
    Peter A. Fasching
    Nina Gottschalk
    Tatiana Besse-Hammer
    Frank Fleischer
    Sven Wind
    Martina Uttenreuther-Fischer
    Martine Piccart
    Nadia Harbeck
    Breast Cancer Research and Treatment, 2012, 134 : 1149 - 1159
  • [38] Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
    Anjie Zhu
    Peng Yuan
    Nanlin Hu
    Mingzhou Li
    Wenmiao Wang
    Xue Wang
    Jian Yue
    Jiayu Wang
    Yang Luo
    Fei Ma
    Pin Zhang
    Qing Li
    Binghe Xu
    Shanbo Cao
    Giuseppe Lippi
    Yoichi Naito
    Mohammed A.Osman
    Gustavo N.Marta
    Gianluca Franceschini
    Armando Orlandi
    Cancer Biology & Medicine, 2021, 18 (03) : 875 - 887
  • [39] Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
    Anjie Zhu
    Peng Yuan
    Nanlin Hu
    Mingzhou Li
    Wenmiao Wang
    Xue Wang
    Jian Yue
    Jiayu Wang
    Yang Luo
    Fei Ma
    Pin Zhang
    Qing Li
    Binghe Xu
    Shanbo Cao
    Giuseppe Lippi
    Yoichi Naito
    Mohammed AOsman
    Gustavo NMarta
    Gianluca Franceschini
    Armando Orlandi
    Cancer Biology & Medicine , 2021, (03) : 875 - 887
  • [40] Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells
    Parsons, Heather A.
    Macrae, Erin R.
    Guo, Hao
    Li, Tianyu
    Barry, William T.
    Tayob, Nabihah
    Wulf, Gerburg M.
    Isakoff, Steven J.
    Krop, Ian E.
    JCO PRECISION ONCOLOGY, 2021, 5 : 896 - 903
12345